Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
7
CLRB Quote, Financials, Valuation and Earnings
Last price:
$5.02
Seasonality move
:
-13.76%
Day range:
$4.88 - $5.30
52-week range:
$4.36 - $94.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
1.18x
Volume:
157.7K
Avg. volume:
908.7K
1-year change:
-93.98%
Market cap:
$9.1M
Revenue:
--
EPS (TTM):
-$21.90
Analysts' Opinion
-
Consensus RatingCellectar Biosciences has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.00, Cellectar Biosciences has an estimated upside of 2280.96% from its current price of $5.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $5.04.
Fair Value
-
According to the consensus of 4 analysts, Cellectar Biosciences has 2280.96% upside to fair value with a price target of $4.00 per share.
CLRB vs. S&P 500
-
Over the past 5 trading days, Cellectar Biosciences has overperformed the S&P 500 by 3.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cellectar Biosciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellectar Biosciences revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Cellectar Biosciences reported revenues of --.
Earnings Growth
-
Cellectar Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cellectar Biosciences reported earnings per share of -$4.20.
Enterprise value:
-4.3M
EV / Invested capital:
--
Price / LTM sales:
137.94x
EV / EBIT:
--
EV / Revenue:
-0.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.4M | -$42.3M | -$46.2M | -$12M | -$6.4M | |
| EBITDA | -$31.2M | -$42M | -$45.9M | -$11.9M | -$6.3M | |
| Diluted EPS | -$124.50 | -$113.10 | -$21.90 | -$27.30 | -$4.20 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $54.4M | $31.4M | $13.8M | $41.4M | $14.9M | |
| Total Assets | $55.1M | $32M | $14.8M | $42.9M | $16M | |
| Current Liabilities | $5M | $4.7M | $7M | $16.3M | $6M | |
| Total Liabilities | $5.3M | $4.8M | $7.5M | $16.7M | $7.8M | |
| Total Equity | $49.8M | $27.2M | $7.3M | $26.2M | $8.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.4M | -$38.6M | -$43.6M | -$13.4M | -$9.4M | |
| Cash From Investing | -$195.9K | -$885.7K | -$82.6K | -$21.6K | -- | |
| Cash From Financing | $9.6M | $66.8M | $17.6M | $43.8M | -- | |
| Free Cash Flow | -$27.6M | -$39.4M | -$43.6M | -$13.4M | -$9.4M | |
CLRB
Sector
Market Cap
$9.1M
$34.4M
Price % of 52-Week High
5.33%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-93.98%
-37.36%
Beta (5-Year)
0.507
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.87
200-day SMA
Sell
Level
$21.40
Bollinger Bands (100)
Sell
Level
6.63 - 10.57
Chaikin Money Flow
Sell
Level
-92.8K
20-day SMA
Sell
Level
$6.63
Relative Strength Index (RSI14)
Sell
Level
36.58
ADX Line
Buy
Level
27.2
Williams %R
Buy
Level
-82.7411
50-day SMA
Sell
Level
$8.01
MACD (12, 26)
Buy
Level
1.34
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
133.6K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Stock Forecast FAQ
In the current month, CLRB has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CLRB average analyst price target in the past 3 months is $4.00.
-
Where Will Cellectar Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellectar Biosciences share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Cellectar Biosciences?
Analysts are divided on their view about Cellectar Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellectar Biosciences is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Cellectar Biosciences's Price Target?
The price target for Cellectar Biosciences over the next 1-year time period is forecast to be $4.00 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CLRB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellectar Biosciences is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CLRB?
You can purchase shares of Cellectar Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellectar Biosciences shares.
-
What Is The Cellectar Biosciences Share Price Today?
Cellectar Biosciences was last trading at $5.02 per share. This represents the most recent stock quote for Cellectar Biosciences. Yesterday, Cellectar Biosciences closed at $5.04 per share.
-
How To Buy Cellectar Biosciences Stock Online?
In order to purchase Cellectar Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
